X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A. The arrangement between Prime and Takeda provides an opportunity to assess clinical outcomes and cost implications with an existing treatment for hemophilia A.
Lead Product(s): Antihemophilic factor recombinant
Therapeutic Area: Genetic Disease Product Name: ADVATE
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 16, 2020
Details:
The arrangement aims to provide financial compensation for Blue Plans that is dependent on the rate at which their members discontinue the two-year treatment with MAVENCLAD or switch to a different MS therapy at any point over the typical course of treatment.
Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Mavenclad
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: EMD Serono
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
